|
Drug R&D doubles as approvals plummet
Interbrew buys top Serbian brewer
Surprising Aspirin
Atkins finds a taker for its ice cream
Drugs
Drug
R&D doubles as approvals plummet
New drug approvals in the US halved
from 53 in 1996 to just 26 in 2002. At the same time, R&D spending
nearly doubled from $17bn in 1996 to $32bn last year, says market
researcher Cutting Edge Information.
Infusing market data into early
product development weeds out commercially risky drugs and shapes products
to better meet patient needs, it says. Industry leaders such as Pfizer,
Novartis and Abbott Laboratories, are using formal tools, processes and
team structures to integrate R&D and commercial players.
"The pharmaceutical industry
must learn to bridge the gap between R&D and commercialisation. Market
dynamics and medical science are changing so rapidly that it is difficult
for the two to stay on the same page," said Cutting Edge senior
analyst Jon Hess. "Until companies pay more attention to this issue,
R&D costs will continue to rise while productivity wanes."
Beer
Interbrew
buys top Serbian brewer
Belgian brewer Interbrew is to buy
50% of leading Serbian brewer Apatin, and make a public offer for the
outstanding shares that values the company at 262m euros.
Apatin is the largest brewer in
southeast Europe, with 39% (5.7m hectolitres) of Serbia’s market. Its
leading brands are Jelen Pivo and Pils light. Interbrew's
Central European network now has 14 breweries.
Drugs
Surprising
Aspirin
Who would believe that a relatively
simple compound like acetylsalicylic acid (ASA), the active ingredient in
Aspirin, would have 3500 academic papers a year written about it?
That’s what Aspirin’s maker,
Bayer Healthcare, is claiming. It has just awarded the 2003 International
Aspirin award, worth €10,000, to Minsheng Yuan (39) for his work on
Aspirin’s effect on diabetes patients.
Originally developed as a pain
killer, ASA is now used to prevent heart attacks and strokes, as a
secondary prevention strategy in diabetic men and women with large vessel
disease, and as a primary prevention strategy in diabetics. It is also
used to treat cardiovascular risk factors such as high blood pressure,
smoking, obesity, high blood lipids, etc.
Researchers have also shown its
benefits in the acute therapy of myocardial infarction and the treatment
of angina pectoris and migraine headaches.
Distribution
Atkins
finds a taker for its ice cream
Following a cautious reception in
the UK for its branded foods, Atkins Nutritionals, has signed Canada’s
CoolBrands International to make, sell and distribute an expanded line-up
of Atkins’ Endulge super premium ice cream products in the US and
Canada. Endulge has no sugar added to reduce its carbohydrate content.
CoolBrands will first market Atkins
Endulge in a range of flavours in pint (450ml) containers, as well as ice
cream bars, fudge bars and frozen snacks. Future line extensions are
planned for soft serve ice cream and bulk ice cream for foodservice
applications.
Atkins diet inventor Robert Atkins
founded Atkins Nutritionals in 1989. The fashionable
carbohydrate-restricted diet has drawn warnings from nutritionists worried
about its long term effects.
|